相关实验视频

Updated: May 15, 2025

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

对可卡因使用障碍 (CURB-2) 进行注射延长释放纳勒和注射延长释放布普伦诺芬的随机,安慰剂对照试验:研究理由和设计

Madhukar H Trivedi¹, Mariah M Kalmin², Thomas Carmody³

¹Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA.

Contemporary clinical trials

|May 13, 2025

概括

这项研究研究了一种针对可卡因使用障碍 (CUD) 的新组合疗法. 这项研究探讨了延长释放注射性纳尔特雷克松 (XR-NTX) 和延长释放注射性布普伦诺芬 (XR-BUP) 作为CUD的潜在治疗方法.

科学领域:

药理学药理学是指药理学的学科.
成药物药物药物药物
临床试验临床试验

背景情况:

可卡因使用障碍 (CUD) 带来了重大的公共卫生挑战,没有FDA批准的治疗方法.
之前的研究 (CURB研究) 表明,延长释放注射性纳尔特雷克松 (XR-NTX) 和布普伦诺芬 (BUP) 在减少可卡因使用方面具有前景.
阿片类药物依赖通常与CUD同时发生,需要有效的双重治疗策略.

研究的目的:

评估CUD新型药物疗法的疗效.
为了确定XR-NTX与延长释放注射性布普伦诺芬 (XR-BUP) 的结合是否在治疗CUD时比安慰剂更有效.
探索这种组合作为"卡帕抗剂"治疗的潜力.

主要方法:

一个IIb期,随机,安慰剂对照试验 (CURB-2研究) 涉及大约426名参与者.
一项多阶段研究,包括1周的药物诱导,8周的积极治疗阶段和4周的随访.
给药XR-NTX,然后给药XR-BUP,旨在阻断片受体并利用卡帕抗剂的作用.

主要成果:

该研究旨在评估尿液验证可卡因使用量的减少.
将组合治疗组和安慰剂组之间的初级结果进行比较.
二次结果可能包括渴望,戒断和整体治疗保留的措施.

结论:

如果有效,XR-NTX和XR-BUP联合治疗可能代表CUD治疗的重大进展.
这种卡帕抗剂方法可能为管理可卡因使用障碍提供了一个新的治疗工具.
根据这项试验的发现,可能需要进一步的研究.

关键词:

这是一种布普伦诺芬.临床试验临床试验是指临床试验的临床试验.可卡因使用障碍是可卡因使用障碍.纳尔特雷克松是一种纳尔特雷克松.治疗方法治疗方法

更多相关视频

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

相关概念视频

Drug Abuse and Addiction: Pharmacological Phenomena

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...